CMAB Biopharma (Suzhou) Inc. and Laekna Therapeutics Shanghai Co. Ltd., have signed a strategic collaboration agreement in Suzhou BioBAY for the speedup of an Immune Checkpoint Inhibitor (ICI) drug candidate for clinical trials and future commercialization.   According to the agreement, CMAB will provide a full spectrum of CMC services for Laekna Therapeutics’ anti-PD-L1 antibody (LAE005). Services to be provided by CMAB include technology transfer, process development, GMP clinical drug s...